Citius Oncology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTOR research report →
Range $6 – $6
Price Chart
About the company
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies.
- CEO
- Leonard L. Mazur
- IPO
- 2022
- Employees
- 285
- HQ
- Cranford, NY, US
Get TickerSpark's AI analysis on CTOR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $79.03M
- P/E
- -1.78
- Fwd P/E
- 8.50
- PEG
- 0.04
- P/S
- 11.12
- P/B
- 2.27
- EV/EBITDA
- -1.69
- Div Yield
- 0.00%
- Gross Margin
- 53.13%
- Op Margin
- -665.63%
- Net Margin
- -648.32%
- ROE
- -102.98%
- ROIC
- -88.72%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-23,522,750
- Net Income
- $-24,761,369-17.1%
- EPS
- $-0.34-13.3%
- OCF Growth
- -4446.6%
- FCF Growth
- -4446.7%
- 52W High
- $2.25
- 52W Low
- $0.49
- 50D MA
- $0.83
- 200D MA
- $0.88
- Beta
- 3.40
- RSI (14)
- 42
- Avg Volume
- 97.59K
No earnings-call transcripts are available for CTOR yet.
- Free Float
- 19.1%
- Shares Outstanding
- 92.98M
- Float Shares
- 17.72M
of shares held by institutions
13 13F filers
Buy/sell ratio 7.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Armistice Capital, LLC | 8.71M | ▼ 483.27K |
| Bank Of America Corp | 3.84M | 0 |
| Vanguard Group Inc | 597.00K | ▲ 416.83K |
| Vanguard Capital Management LLC | 546.33K | ▲ 11.50K |
| Ubs Group AG | 334.62K | ▲ 297.78K |
| Geode Capital Management, LLC | 245.41K | ▼ 19.33K |
| Vanguard Fiduciary Trust Co | 121.91K | 0 |
| Ifp Advisors, Inc | 107.42K | 0 |
| Citadel Advisors LLC | 90.59K | ▲ 90.59K |
| Northern Trust Corp | 45.75K | 0 |
| State Street Corp | 42.90K | 0 |
| Virtu Financial LLC | 21.88K | ▲ 21.88K |
Held by 21 ETFs
Biggest fund positions in CTOR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 10, 26 | Peri Jonathan | other | 0 |
| Sep 19, 25 | HOLUBIAK MYRON Z | other | 850,000 |
| Sep 19, 25 | HOLUBIAK MYRON Z | other | 100,000 |
| Sep 19, 25 | Smith Robert Joseph | other | 300,000 |
| Sep 19, 25 | Mazur Leonard L | other | 1,700,000 |
| Sep 19, 25 | Webb Carol | other | 300,000 |
| Sep 19, 25 | Czuczman Myron | other | 825,000 |
| Sep 19, 25 | MCGRATH DENNIS M | other | 300,000 |
| Sep 19, 25 | Bartushak Jaime | other | 825,000 |
| Sep 19, 25 | Mayersohn Joel David | other | 300,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CTOR coverage
Recent articles, reports, and earnings notes.
No research on CTOR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CTOR report →Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
prnewswire.com · Sep 3
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
prnewswire.com · Aug 14
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
prnewswire.com · Aug 14
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
prnewswire.com · Aug 12
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
prnewswire.com · Aug 5
Citius Oncology (NASDAQ:CTOR) Stock Price Up 0.6% – Here’s What Happened
defenseworld.net · Jul 23
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
prnewswire.com · Jul 21
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
prnewswire.com · Jun 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.